126 related articles for article (PubMed ID: 33823338)
1. Histological growth patterns and molecular analysis of resected colorectal lung metastases.
Pilozzi E; Fedele D; Montori A; Lorenzon L; Peritore V; Mannocchi G; Bagheri N; Leone C; Palumbo A; Roberto M; Ranazzi G; Rendina E; Balducci G; Ibrahim M
Pathol Res Pract; 2021 Jun; 222():153414. PubMed ID: 33823338
[TBL] [Abstract][Full Text] [Related]
2. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutation in lung metastases from colorectal cancer: prognostic implications.
Ghidini M; Personeni N; Bozzarelli S; Baretti M; Basso G; Bianchi P; Tronconi MC; Pressiani T; Grizzi F; Giordano L; Malesci A; Alloisio M; Laghi L; Santoro A; Rimassa L
Cancer Med; 2016 Feb; 5(2):256-64. PubMed ID: 26715198
[TBL] [Abstract][Full Text] [Related]
4. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
5. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
[TBL] [Abstract][Full Text] [Related]
6. KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer.
Renaud S; Guerrera F; Seitlinger J; Costardi L; Schaeffer M; Romain B; Mossetti C; Claire-Voegeli A; Filosso PL; Legrain M; Ruffini E; Falcoz PE; Oliaro A; Massard G
Oncotarget; 2017 Jan; 8(2):2514-2524. PubMed ID: 27911859
[TBL] [Abstract][Full Text] [Related]
7. KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.
Renaud S; Romain B; Falcoz PE; Olland A; Santelmo N; Brigand C; Rohr S; Guenot D; Massard G
Br J Cancer; 2015 Feb; 112(4):720-8. PubMed ID: 25688918
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
9. RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.
Osumi H; Shinozaki E; Suenaga M; Matsusaka S; Konishi T; Akiyoshi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Mise Y; Ishizawa T; Inoue Y; Takahashi Y; Saiura A; Uehara H; Mun M; Okumura S; Mizunuma N; Miki Y; Yamaguchi T
Int J Cancer; 2016 Aug; 139(4):803-11. PubMed ID: 27004837
[TBL] [Abstract][Full Text] [Related]
10. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
11. Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.
Neumann J; Wehweck L; Maatz S; Engel J; Kirchner T; Jung A
Virchows Arch; 2013 Oct; 463(4):509-23. PubMed ID: 23934607
[TBL] [Abstract][Full Text] [Related]
12. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
13. Is complete liver resection without resection of synchronous lung metastases justified?
Mise Y; Kopetz S; Mehran RJ; Aloia TA; Conrad C; Brudvik KW; Taggart MW; Vauthey JN
Ann Surg Oncol; 2015 May; 22(5):1585-92. PubMed ID: 25373535
[TBL] [Abstract][Full Text] [Related]
14. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
15. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.
Huang CJ; Teng HW; Chien CC; Lin JK; Yang SH
PLoS One; 2014; 8(6):e65117. PubMed ID: 23755178
[TBL] [Abstract][Full Text] [Related]
17. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
[TBL] [Abstract][Full Text] [Related]
18. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
[TBL] [Abstract][Full Text] [Related]
19. Biomarker alterations associated with distinct patterns of metastatic spread in colorectal cancer.
Michl M; Taverna F; Kumbrink J; Schiergens TS; Heinemann V; Engel J; Kirchner T; Neumann J
Virchows Arch; 2021 Apr; 478(4):695-705. PubMed ID: 33300106
[TBL] [Abstract][Full Text] [Related]
20. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
